Prosecution Insights
Prosecution Insights
48 pending office actions • 34 clients • 46 examiners • 24 art units • 0 of 48 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (6%) |
| §103 only | 12 (25%) |
| §102 only | 1 (2%) |
| §112 only | 8 (17%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 11 (23%) |
| Multi-statute (no §101) | 11 (23%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 2 | 59.4% | +47.9% |
| BUNNER, BRIDGET E | 2 | 64.4% | +20.1% |
| HUI, SAN MING R | 1 | 59.3% | +19.9% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| OLSON, ANDREA STEFFEL | 1 | 62.2% | -11.9% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.5% |
| SCHMITT, MICHAEL J | 1 | 56.6% | +21.7% |
| SWITZER, JULIET CAROLINE | 1 | 42.3% | +53.8% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.1% | +48.8% |
| MOSHER, ERIC PARKER | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 104d overdue |
| 18035246 | METHOD FOR ENZYMATIC AND/OR MICROBIAL PROCESSING OF WASTE COMPRISING RECIRCULATION OF PROCESS WATER | ZINGARELLI, SANDRA | 66d overdue |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | HSU, GRACE CHING | 46d overdue |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
| 18282402 | TMEM173 saRNA Compositions and Methods of Use | HUDSON, AMY ROSE | 9d overdue |
| 17637410 | BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS | MYERS, CARLA J | 2d overdue |
| 18050333 | Methods of in Vitro Cell Delivery | ZHU, JIANJIAN | 6d |
| 18251523 | Combination Treatment of Cancer | XIAO, YAN | 8d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911808 | Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection | BUNNER, BRIDGET E | 9d |
| 18850107 | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof | HUI, SAN MING R | — |
| 18739986 | AAV Vectors | BLUMEL, BENJAMIN P | — |
| 18708367 | Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration | KATAKAM, SUDHAKAR | — |
| 18695940 | SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure | SCHMITT, MICHAEL J | — |
| 18606338 | Methods of Using Donor-Derived Cell-Free DNA to Distinguish Acute Rejection and Other Conditions in Liver Transplant Recipients | SWITZER, JULIET CAROLINE | — |
| 18690358 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | TOWNSLEY, SARA ELIZABETH | — |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1654 | 4 |
| 1647 | 4 |
| 1636 | 3 |
| 1642 | 3 |
| 1671 | 2 |
| 1629 | 2 |
| 1653 | 2 |
| 1658 | 2 |
| 1631 | 2 |
| 1627 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18850107 | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof | Ildong Pharmaceutical Co., Ltd. | HUI, SAN MING R | §103 | Non-Final OA | — | Pending | Sep 24, 2024 | |
| 18739986 | AAV Vectors | Vigeneron GmbH | BLUMEL, BENJAMIN P | 1671 | §112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18710370 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation | OLSON, ANDREA STEFFEL | §102§103§112DP | Non-Final OA | — | Pending | May 15, 2024 | |
| 18708367 | Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration | Breye Therapeutics Aps | KATAKAM, SUDHAKAR | §112 | Non-Final OA | — | Pending | May 08, 2024 | |
| 18695940 | SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure | Haihe Biopharma Co., Ltd. | SCHMITT, MICHAEL J | 1629 | §102§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18606338 | Methods of Using Donor-Derived Cell-Free DNA to Distinguish Acute Rejection and Other Conditions in Liver Transplant Recipients | Northwestern University | SWITZER, JULIET CAROLINE | §101§102§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 | |
| 18690358 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | Haihe Biopharma Co., Ltd. | TOWNSLEY, SARA ELIZABETH | 1629 | §102§103§112Other | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18434621 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. | MOSHER, ERIC PARKER | DP | Non-Final OA | — | Pending | Feb 06, 2024 | |
| 18431656 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. | DONOHUE, SEAN R | §102§103DP | Non-Final OA | — | Pending | Feb 02, 2024 | |
| 18415032 | Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four | Intellia Therapeutics, Inc. | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | 50d overdue | Pending | Jan 17, 2024 |
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | Lapix Therapeutics, Inc. | PIPIC, ALMA | 1617 | §103 | Non-Final OA | 53d | Pending | Jan 17, 2024 |
| 18569054 | Improving the Efficiency of PAL-Catalyzed Protein Ligation By A Cascade Enzymatic Scheme | Nanyang Technological University | KOROTCHKINA, LIOUBOV G | 1653 | §103§112DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18513964 | Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation | Csl Behring LLC | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 70d | Pending | Nov 20, 2023 |
| 18511857 | USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER | Remegen Co., Ltd. | EDGINGTONGIORDANO, FRANCESCA | §102§103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 | |
| 18507778 | Compositions and Methods for Targeting Cancer Stem Cells | The General Hospital Corporation | COOK, LISA V | 1642 | §103§112DP | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18557661 | Topical Compositions Comprising (Glyco)Sphingolipids and/or (Glyco)Ceramides | Carbocode S.A. | KRISHNAN, GANAPATHY | 1693 | §103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | Aardvark Therapeutics, Inc. | HIBBERT, CATHERINE S | 1658 | §103 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18374902 | PREPARATION AND PURIFICATION PROCESS OF MONOMETHYL AURISTAIN E COMPOUND | Remegen Co., Ltd. | HA, JULIE | 1654 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18282402 | TMEM173 saRNA Compositions and Methods of Use | Mina Therapeutics Limited | HUDSON, AMY ROSE | 1636 | §102§112 | Non-Final OA | 9d overdue | Pending | Sep 15, 2023 |
| 18450966 | USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER | Remegen Co., Ltd. | PUTTLITZ, KARL J | 1646 | §103§112DPOther | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | Intellia Therapeutics, Inc. | SMALL, KATHERINE R | 1633 | §102 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18334680 | Glycan-Interacting Compounds and Methods of Use | Seagen Inc. | BORGEEST, CHRISTINA M | 1675 | §112Other | Non-Final OA | 13d | Pending | Jun 14, 2023 |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | Intellia Therapeutics, Inc. | KIM, TAEYOON | 1631 | §103 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18253485 | Method for Treating Antibody-Mediated Rejection | Csl Behring GmbH | HIBBERT, CATHERINE S | 1658 | §103§112DP | Final Rejection | — | Pending | May 18, 2023 |
| 18035246 | METHOD FOR ENZYMATIC AND/OR MICROBIAL PROCESSING OF WASTE COMPRISING RECIRCULATION OF PROCESS WATER | Renescience A/S | ZINGARELLI, SANDRA | 1653 | §103§112 | Non-Final OA | 66d overdue | Pending | May 03, 2023 |
| 18251523 | Combination Treatment of Cancer | Glaxosmithkline Intellectual Property (No. 4) Ltd. | XIAO, YAN | 1642 | §103§112 | Non-Final OA | 8d | Pending | May 02, 2023 |
| 18304993 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | The Scripps Research Institute | FLINDERS, JEREMY C | 1684 | §112 | Final Rejection | 10d overdue | Pending | Apr 21, 2023 |
| 18302313 | Heterocyclic Compounds as RET Kinase Inhibitors | Cancer Research Technology Limited | HSU, GRACE CHING | 1627 | §102§112Other | Non-Final OA | 46d overdue | Pending | Apr 18, 2023 |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | Sorrento Therapeutics, Inc. | HAMA, JOANNE | 1647 | §103§112 | Final Rejection | 104d overdue | Pending | Apr 06, 2023 |
| 18182308 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | Alpine Immune Sciences, Inc. | MOSELEY II, NELSON B | 1642 | DP | Non-Final OA | — | Pending | Mar 10, 2023 |
| 17792976 | Cytokine Prodrugs Comprising a Cleavable Linker | Trutino Biosciences Inc. | STOICA, ELLY GERALD | 1647 | §112 | Final Rejection | — | Pending | Nov 07, 2022 |
| 17923208 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS WITH AND WITHOUT A T CELL INHIBITORY PROTEIN AND METHODS OF USE THEREOF | Alpine Immune Sciences, Inc. | BUNNER, BRIDGET E | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Nov 03, 2022 |
| 18050333 | Methods of in Vitro Cell Delivery | Intellia Therapeutics, Inc. | ZHU, JIANJIAN | 1631 | §102§103§112Other | Non-Final OA | 6d | Pending | Oct 27, 2022 |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | Avm Biotechnology, LLC | HAVLIN, ROBERT H | 1626 | §103§112Other | Final Rejection | 23d overdue | Pending | Oct 25, 2022 |
| 17911808 | Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection | Vitaeris Inc. | BUNNER, BRIDGET E | 1647 | §102§103§112 | Non-Final OA | 9d | Pending | Sep 15, 2022 |
| 17910415 | Fetuin A for Treatment of Renal Disorders | Universitaet Bern | MARTINEZ, TARA L | 1654 | §103 | Final Rejection | — | Pending | Sep 09, 2022 |
| 17905431 | Barley Plants with High Limit Dextrinase Activity | Carlsberg A/S | MEADOWS, CHRISTINA L | 1663 | §103 | Non-Final OA | — | Pending | Sep 01, 2022 |
| 17817777 | Composition and Methods for Selective Degradation of Engineered Proteins | Celgene Corporation | BOWLES, DAVID PAUL | 1654 | §112 | Non-Final OA | — | Pending | Aug 05, 2022 |
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | Aardvark Therapeutics, Inc. | IVANOVA, SVETLANA M | 1627 | §103 | Non-Final OA | 60d overdue | Pending | Jun 21, 2022 |
| 17824450 | DISTANCE DOMINANT INTRAOCULAR LENS | Bausch & Lomb Incorporated | RIOS, GABRIELLA GISELLE BONO | 3774 | §103 | Non-Final OA | — | Pending | May 25, 2022 |
| 17735929 | Methods and Compositions for Directed Genome Editing | Intellia Therapeutics, Inc. | HASAN, KHALEDA B | 1636 | §103§112DP | Non-Final OA | — | Pending | May 03, 2022 |
| 17637410 | BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS | Northwestern University | MYERS, CARLA J | 1682 | §101§102§103§112 | Non-Final OA | 2d overdue | Pending | Feb 22, 2022 |
| 17532363 | URINE BIOMARKERS | Exosome Diagnostics, Inc. | POHNERT, STEVEN C | 1683 | §101§103§112DP | Final Rejection | — | Pending | Nov 22, 2021 |
| 17469665 | Compositions and Methods for Treatment of Duchenne Muscular Dystrophy | Vertex Pharmaceuticals Incorporated | TATGE, LEXUS MARC | 1600 | §103DP | Non-Final OA | — | Pending | Sep 08, 2021 |
| 17056103 | Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases | The Queensland Institute of Medical Research | GILL, RACHEL B | 1671 | §103 | Final Rejection | — | Pending | Jul 01, 2021 |
| 17339425 | GENE-EDITING SYSTEMS FOR EDITING A CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR (CFTR) GENE | Vertex Pharmaceuticals Incorporated | JOHNSON, ALLISON MARIE | 1638 | §112 | Non-Final OA | — | Pending | Jun 04, 2021 |
| 16845280 | GENE-EDITING SYSTEMS FOR MODIFYING A SCN9A OR SCN10A GENE AND METHODS OF USE THEREOF | Vertex Pharmaceuticals Incorporated | SHIN, DANA H | 1635 | §103 | Final Rejection | 49d overdue | Pending | Apr 10, 2020 |
| 15550951 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES | William Marsh Rice University | CANDELARIA, JULIANA IRENE | 1600 | §103DP | Final Rejection | — | Pending | Aug 14, 2017 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial